Ovid Therapeutics (NASDAQ:OVID) and Sernova Biotherapeutics (OTCMKTS:SEOVF) Head to Head Contrast

Ovid Therapeutics (NASDAQ:OVID) and Sernova Biotherapeutics (OTCMKTS:SEOVF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Institutional & Insider Ownership

72.2% of Ovid Therapeutics shares are owned by institutional investors. 13.1% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Ovid Therapeutics and Sernova Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Sernova Biotherapeutics	N/A	N/A	-761.41%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Ovid Therapeutics and Sernova Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1	0	7	1	2.89
Sernova Biotherapeutics	0	0	0	0	0.00

Ovid Therapeutics currently has a consensus target price of $5.13, indicating a potential upside of 100.98%. Given Ovid Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Ovid Therapeutics is more favorable than Sernova Biotherapeutics.

Volatility & Risk

Ovid Therapeutics has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, Sernova Biotherapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Valuation and Earnings

This table compares Ovid Therapeutics and Sernova Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25 million	46.39	-$17.41 million	($0.29)	-8.79
Sernova Biotherapeutics	N/A	N/A	-$11.24 million	($0.04)	-2.94

Sernova Biotherapeutics has lower revenue, but higher earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Sernova Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Ovid Therapeutics beats Sernova Biotherapeutics on 8 of the 14 factors compared between the two stocks.

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

About Sernova Biotherapeutics

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.